Recruiting

Testing a new chemotherapy drug for advanced cervical cancer with kidney problems

Plain-English translation of NCT03101995 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a chemotherapy drug, given weekly alongside radiation therapy for women with advanced cervical cancer who also have reduced kidney function. Normally, doctors use a different chemotherapy drug called cisplatin for this treatment, but it can be hard on the kidneys. This study wants to see if is a safer alternative for patients whose kidneys are already weakened.

Cervical cancer is a leading cause of cancer death in Mexico, and combining chemotherapy with radiation improves survival rates. However, the standard chemotherapy drug (cisplatin) can damage the kidneys, making it risky for patients who already have kidney problems. This medication may offer the same cancer-fighting benefit with less kidney damage.

Do you qualify?

You likely qualify if…

you are a woman between 18 and 70 years old
you have been diagnosed with advanced cervical cancer (stages IB2 through IVA)
you have reduced kidney function, defined as a glomerular filtration rate below 60
you have not received any previous cancer treatment
you are willing and able to use approved contraception during treatment and for 12 weeks after (if of childbearing age)
your blood counts and liver function are normal or near-normal

You likely don't qualify if…

you have another active cancer (other than non-melanoma skin cancer)
you have diabetes or high blood pressure with complications affecting your eyes or kidneys
you have HIV infection or active tuberculosis
you have or have had lupus or other diseases that damage the kidneys
you have uncontrolled heart disease, severe high blood pressure, or active infections

What participation looks like

You would receive the medication as a weekly injection for 6 weeks while undergoing radiation therapy to the pelvis. During this time, the research team would carefully monitor your kidney function with blood tests before, during, and after treatment to make sure the medication is safe for you. The entire treatment course lasts about 6 weeks, with follow-up visits to check your health and cancer response.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

Mexico

National Institute of Cancer, Mexico City, Mexico City

Key details

Phase

Testing effectiveness

Sponsor

National Institute of Cancerología

Collaborators

Instituto Nacional de Cardiologia Ignacio Chavez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Enrollment target

~18 participants

Started

January 2018

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Sex

Female only

Last updated on clinicaltrials.gov in May 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Lucely C Cetina, MD, M.Sc.

National Institute of Cancerología

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.